Paper Details

  1. Home
  2. Paper Details

Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.

Author: DeviPoornaganga, GomathyN S, GuleriaRandeep, JawaharShaheed, KadamAbhijeet, KumarHemanth, MamulwarMegha, ManeAarti, MenonJaykumar, MohanAnant, PadmapriydarsiniChandrasekaran, PavankumarNathella, RameshP M, ReddyDevaraju, SekarLakshmanan, ShandilR K, ShanmugamPrema, SinghManjula, SinghUrvashi B, SureshChandra

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the potential of metformin as an adjunctive therapy to anti-tuberculosis treatment (ATT) in adults with pulmonary tuberculosis (PTB). The study aims to determine if metformin can shorten the time to sputum culture conversion and reduce tissue inflammation.
Paper Details　
Original Abstract of the Article :
Metformin, by reducing intracellular Mycobacterium tuberculosis growth, can be considered an adjunctive therapy to anti-tuberculosis treatment (ATT). We determined whether metformin with standard ATT reduces time to sputum culture conversion and tissue inflammation in adults with pulmonary tuberculo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427151/

データ提供：米国国立医学図書館（NLM）

Metformin: A Potential Oasis in the Desert of Tuberculosis Treatment

Tuberculosis (TB) is a serious infectious disease that continues to be a major public health concern. This study explores the potential role of metformin, a medication commonly used to treat diabetes, as an adjunctive therapy for TB. The researchers conducted a randomized trial investigating the effects of metformin, in combination with standard anti-TB drugs, on sputum conversion time and tissue inflammation in adults with pulmonary TB. This study explores the potential benefits of repurposing existing medications to enhance TB treatment strategies.

Expanding the Arsenal: New Strategies for TB Treatment

The study found that metformin, when combined with standard anti-TB drugs, did not significantly reduce sputum conversion time or tissue inflammation. This finding suggests that metformin may not be an effective adjunctive therapy for TB. It's a reminder that the journey to finding effective TB treatments is ongoing and requires continued exploration of different approaches.

Conquering Tuberculosis: A Multifaceted Approach

TB is a complex and challenging disease that requires a multifaceted approach to treatment. This study underscores the importance of ongoing research to develop new and improved treatment strategies. It encourages us to remain vigilant in the fight against TB, exploring innovative solutions to address this global health concern. It's a reminder that conquering the desert of TB requires continuous exploration and a commitment to collaborative efforts.

Dr.Camel's Conclusion

This study explores the potential of metformin as an adjunctive therapy for TB, but the findings suggest it may not be a viable option. It's a reminder that the journey to finding effective TB treatments is an ongoing process, requiring continued research and a commitment to developing innovative solutions for this global health challenge.

Date :
  1. Date Completed 2022-09-02
  2. Date Revised 2022-11-27
Further Info :

Pubmed ID

34849651

DOI: Digital Object Identifier

PMC9427151

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.